The protective effect of simvastatin on monocrotaline-induced pulmonary hypertension in rats

Korean Circulation Journal

Volumn 38, Issue 6, 2008, Pages 313-319

  Mi, Young Kim ^a   Young, Kyu Kim ^a   Yong, Wook Jung ^a   Woo, Taek Kim ^b   Tae, Hwan Kwon ^c   Dong, Seok Lee ^a  

^a Dongguk University College of Medicine   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

Author keywords

Pulmonary circulation; Pulmonary hypertension; Statins

Indexed keywords

AQUAPORIN 1; AQUAPORIN 2; MONOCROTALINE; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; KIDNEY FUNCTION; LUNG ARTERY; LUNG CIRCULATION; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT;

EID: 48349129130     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2008.38.6.313     Document Type: Article

References (28)

1. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (Suppl): 13S-24S.
2. Martin KB, Klinger JR, Rounds SI. Pulmonary arterial hypertension: new insights and new hope. Respirology 2006; 11: 6-17.
3. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005; 258: 199-215.
4. Kunieda T, Nakanishi N, Satoh T, Kyotani S, Okano Y, Nagaya N. Prognoses of primary pulmonary hypertension and chronic major vessel thromboembolic pulmonary hypertension determined from cumulative survival curves. Intern Med 1999; 38: 543-6.
5. Puri A, McGoon MD, Kushwaha SS. Pulmonary arterial hypertension: current therapeutic strategies. Nat Clin Pract Cardiovasc Med 2007; 4: 319-29
6. Kao PN. Simvastatin treatment of pulmonary hypertension an observational case series. Chest 2005; 127: 1446-52.
7. Hu H, Sung A, Zhao G, et al. Simvastatin enhances bone mor phogenetic protein receptor type II expression. Biochem Biophys Res Commun 2006; 339: 59-64.
8. Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003; 285: H938-45.
9. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003; 108: 1640-5.
10. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291: L668-76.
11. King LS, Nielsen S, Agre P. Aquaporin-1 water channel protein in lung: ontogeny, steroid-induced expression, and distribution in rat. J Clin Invest 1996; 97: 2183-91.
12. King LS, Yasui M. Aquaporins and disease: lessons from mice to humans. Trends Endocrinol Metab 2002; 13: 355-60.
13. Nielsen S, Terris J, Andersen D, et al. Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc Natl Acad Sci U S A 1997; 94: 5450-5.
14. Reindel JF, Ganey PE, Wagner JG, Slocombe RF, Roth RA. Development of morphologic, hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole. Toxicol Appl Pharmacol 1990; 106: 179-200.
15. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343-9.
16. Lee WD, Kim DS, Lee JH, et al. A clinical review of primary pulmonary hypertension. Korean Circ J 2003; 33: 507-12.
17. Lee WS, Kim KH, Jeong DH, et al. Clinical characteristics and prognostic factors of patients with severe pulmonary hypertension. Korean Circ J 2007; 37: 265-70.
18. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 39-45.
19. Newman JH, Fanburg BL, Archer SL, et al. Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workhop. Circulation 2004; 109: 2947-52.
20. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methyl- glutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9.
21. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725-9.
22. Son JW, Koh KK, You SM, et al. Effects of simvastatin alone or combined with ramipril on nitric oxide bioactivity and inflammation markers in hypercholesterolemic patients. Korean Circ J 2003; 33: 1053-9
23. Girgis RE, Mozammel S, Champion HC, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1105-10.
24. Hales CA, Du HK, Volokhov A, Mourfarrej R, Quinn DA. Aquaporin channels may modulate ventilator-induced lung injury. Respir Physiol 2001; 124: 159-66.
25. Su X, Song Y, Jiang J, Bai C. The role of aquaporin-1 (AQP1) expression in a murine model of lipopolysaccharide-induced acute lung injury. Respir Physiol Neurobiol 2004; 142: 1-11.
26. Agre P, King LS, Yasui M, et al. Aquaporin water channels-from atomic structure to clinical medicine. J Physiol 2002; 542: 3-16.
27. Staahltoft D, Nielsen S, Janjua NR, et al. Losartan treatment normalizes renal sodium and water handling in rats with mild congestive heart failure. Am J Physiol Renal Physiol 2002; 282: F307-15.
28. Yu CM, Wing-Hon Lai K, Li PS, Lam KY, Leung JC, Lai KN. Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action. J Mol Cell Cardiol 2004; 36: 445-53.